Eribulin mesylate regulatory update

FDA extended the PDUFA date for an NDA from Eisai for eribulin mesylate by 3 months to Dec. 30 from Sept. 30. The NDA is under Priority Review to treat locally advanced or metastatic breast cancer in ...